JP2023539476A - アネキシンａ１のｎ末端ペプチド製剤及び方法 - Google Patents

アネキシンａ１のｎ末端ペプチド製剤及び方法 Download PDF

Info

Publication number
JP2023539476A
JP2023539476A JP2023512755A JP2023512755A JP2023539476A JP 2023539476 A JP2023539476 A JP 2023539476A JP 2023512755 A JP2023512755 A JP 2023512755A JP 2023512755 A JP2023512755 A JP 2023512755A JP 2023539476 A JP2023539476 A JP 2023539476A
Authority
JP
Japan
Prior art keywords
pharmaceutical formulation
liquid pharmaceutical
solution
formulation according
annexin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023512755A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539476A5 (cg-RX-API-DMAC10.html
Inventor
トルプ ブクリンスキー，イェンス
ソンダービー トゥエルング，ペルニレ
ハンブルグ イェンセン，メッテ
Original Assignee
リゾサー ファーマ エー／エス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リゾサー ファーマ エー／エス filed Critical リゾサー ファーマ エー／エス
Publication of JP2023539476A publication Critical patent/JP2023539476A/ja
Publication of JP2023539476A5 publication Critical patent/JP2023539476A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2023512755A 2020-08-21 2021-08-20 アネキシンａ１のｎ末端ペプチド製剤及び方法 Pending JP2023539476A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20192142 2020-08-21
EP20192142.6 2020-08-21
PCT/EP2021/073186 WO2022038281A1 (en) 2020-08-21 2021-08-20 Annexin a1 n-terminal peptide formulations and methods

Publications (2)

Publication Number Publication Date
JP2023539476A true JP2023539476A (ja) 2023-09-14
JP2023539476A5 JP2023539476A5 (cg-RX-API-DMAC10.html) 2024-08-27

Family

ID=72193322

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023512755A Pending JP2023539476A (ja) 2020-08-21 2021-08-20 アネキシンａ１のｎ末端ペプチド製剤及び方法

Country Status (10)

Country Link
US (2) US20230295255A1 (cg-RX-API-DMAC10.html)
EP (3) EP4595950A3 (cg-RX-API-DMAC10.html)
JP (1) JP2023539476A (cg-RX-API-DMAC10.html)
CN (1) CN116323649A (cg-RX-API-DMAC10.html)
AU (1) AU2021327733A1 (cg-RX-API-DMAC10.html)
CA (1) CA3192030A1 (cg-RX-API-DMAC10.html)
ES (1) ES3031633T3 (cg-RX-API-DMAC10.html)
HU (1) HUE071875T2 (cg-RX-API-DMAC10.html)
PL (1) PL4200319T3 (cg-RX-API-DMAC10.html)
WO (2) WO2022038258A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3031633T3 (en) * 2020-08-21 2025-07-10 Resother Pharma As Annexin a1 n-terminal peptide formulations and methods
US20250345392A1 (en) 2022-06-30 2025-11-13 Resother Pharma A/S Annexin a1 liquid pharmaceutical composition
EP4680262A1 (en) 2023-03-13 2026-01-21 Resother Pharma A/S Annexin a1 delayed dosing
AU2024234229A1 (en) 2023-03-13 2025-09-25 Resother Pharma A/S Annexin a1 administration regime
WO2025083394A1 (en) 2023-10-16 2025-04-24 Therakind Limited Antimicrobial use of annexin a1 protein
WO2025083393A1 (en) 2023-10-16 2025-04-24 Therakind Limited Antimicrobial use of peptides derived from annexin a1

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014519526A (ja) * 2011-06-15 2014-08-14 ユージーピー・セラピューティクス・インコーポレイテッド 抗炎症医薬製品

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9283260B2 (en) * 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
WO2013053888A1 (en) * 2011-10-14 2013-04-18 Baxter International Inc. Protein purification by anion exchange chromatography
HUE052977T2 (hu) 2014-04-22 2021-06-28 Txp Pharma Gmbh Elágazó szénláncú aminosav-próbával rendelkezõ peptid analóg(ok)
CN110302176A (zh) * 2019-06-25 2019-10-08 中国人民解放军陆军军医大学 一种抗炎多肽纳米药物及制备方法
ES3031633T3 (en) * 2020-08-21 2025-07-10 Resother Pharma As Annexin a1 n-terminal peptide formulations and methods
US20250345392A1 (en) * 2022-06-30 2025-11-13 Resother Pharma A/S Annexin a1 liquid pharmaceutical composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014519526A (ja) * 2011-06-15 2014-08-14 ユージーピー・セラピューティクス・インコーポレイテッド 抗炎症医薬製品

Also Published As

Publication number Publication date
EP4200319C0 (en) 2025-04-16
EP4200319B1 (en) 2025-04-16
AU2021327733A9 (en) 2023-04-27
CA3192030A1 (en) 2022-02-24
US20230295255A1 (en) 2023-09-21
EP4200319A1 (en) 2023-06-28
WO2022038258A1 (en) 2022-02-24
AU2021327733A1 (en) 2023-04-20
EP4595950A2 (en) 2025-08-06
ES3031633T3 (en) 2025-07-10
PL4200319T3 (pl) 2025-08-18
HUE071875T2 (hu) 2025-09-28
CN116323649A (zh) 2023-06-23
EP4595950A3 (en) 2025-10-29
EP4200320A1 (en) 2023-06-28
US20240041977A1 (en) 2024-02-08
WO2022038281A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
EP4200319B1 (en) Annexin a1 n-terminal peptide formulations and methods
CN102614134B (zh) Vegf拮抗剂制剂
JP4353544B2 (ja) アミリン作動薬ペプチド用製剤
JP7580404B2 (ja) Ｇｌｐ１／２二重アゴニストの非経口医薬組成物
EP3065765B1 (en) Use of il-22 dimers in manufacture of medicaments for treating pancreatitis
TWI921427B (zh) Glp-1/glp-2雙重促效劑之醫藥組合物
JP7751641B2 (ja) Ｇｌｐ－１／ｇｌｐ－２デュアルアゴニストの医薬組成物
TW202500183A (zh) 包括環糊精的醫藥調配物
WO2019061395A1 (zh) 兴奋性神经毒性相关损伤的治疗肽组合物
KR20230121824A (ko) Glp-1/glp-2 이중 효능제의 약학적 조성물
JP2004521911A (ja) 投薬方式
KR102956482B1 (ko) 글루카곤 유사체의 액체 제형
KR20230117342A (ko) 펩타이드 제제 및 이의 안과적 용도
CN113289029A (zh) 一种单克隆抗体-细胞因子融合蛋白制剂
CZ9904142A3 (cs) Nové BPC peptidové sole s organo-protektivní aktivitou, proces jejich přípravy a jejich pouľití v léčbě
JP2026507871A (ja) アネキシンａ１投与レジメン
RU2852511C1 (ru) Фармацевтическая композиция двойных агонистов glp-1/glp-2
RU2855486C1 (ru) Фармацевтическая композиция двойных агонистов glp-1/glp-2
WO2026012337A1 (zh) 一种包含psd-95多肽抑制剂的药物组合物及其制备方法
CN115867307A (zh) Il-2融合多肽组合物以及其制备和使用方法
HK40095698B (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
HK40095698A (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
EA045982B1 (ru) СТАБИЛЬНЫЙ ЛИОФИЛИЗИРОВАННЫЙ СОСТАВ НА ОСНОВЕ G-CSF, СЛИТОГО С ГИБРИДНЫМ Fc
EA050539B1 (ru) Жидкие составы аналогов глюкагона
EA044400B1 (ru) Пептидная композиция для лечения повреждений, связанных с возбуждающей нейротоксичностью

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240816

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240816

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260129

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260723